Heidmar reports triple-digit revenue growth in Q4 2025
Heidmar Maritime Holdings (NASDAQ:HMR) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a period of rapid institutional scaling.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Heidmar Maritime Holdings (NASDAQ:HMR) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a period of rapid institutional scaling.
Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).
NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.
Concentrix (NASDAQ:CNXC) today reported its financial results for the fiscal first quarter ended February 28, 2026, demonstrating steady top-line expansion and a continued commitment to shareholder returns.
Core & Main (NYSE:CNM) today reported financial results for the fourth quarter and fiscal year ended February 1, 2026, showcasing a year of disciplined margin management and robust cash generation.
Fennec Pharmaceuticals (NASDAQ:FENC) today reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a year of aggressive commercial scaling and a total recapitalization of the company’s balance sheet.
Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.
Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.
LightInTheBox Holding (NYSE:LITB) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2025, marking a definitive shift from high-volume scaling to high-margin profitability.
VersaBank (NASDAQ:VBNK) today announced it has reached a definitive agreement to sell the assets associated with its sole U.S. retail branch in Holdingford, Minnesota, to Stearns Bank National Association.
The Buckle (NYSE:BKE) today announced that its Board of Directors has authorized a quarterly cash dividend of $0.35 per share.
BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade